0.16
-1.93%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Acarix
Its shares trade on Nasdaq Stockholm under the ticker ACARIX.ST. It has been listed since 19 December 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 7.4m and a net loss of SEK 48.1m. At that date it held total assets of SEK 48.3m and shareholders' equity of SEK 38.2m.
Acarix AB is engaged in the provision of medical devices for monitoring Coronary Artery Disease. The company is headquartered in Malmo, Skane. The company went IPO on 2016-12-19. The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Dec 2016
- Employees
- 9
- Website
- acarix.com ↗
Leadership
Pay as last reported
- Mr. Jan PoulsenChairman of the Board, since 2025
- Mr. Aamir MahmoodPresident, Chief Executive OfficerSEK 5.2m
- Mr. Christian LindholmChief Financial Officer
- Mr. Daniel BurkeHead of Reimbursement & Market Access
- Dr. George ChrysantChief Medical Advisor
- Ms. Carma ConnelyHead of Operations & Customer Excellence
- Ms. Jennifer MatsonHead of Medical Affairs
- Mr. Dwyndl NelmsHead of QA, RA & Production
- Mr. Jeffrey RuddHead of U.S. Finance
- Mr. Jeff ThomasHead of U.S. Sales
- Mr. Tony DasIndependent DirectorSEK 247,000
- Ms. Marlou Janssen-CounotteIndependent DirectorSEK 345,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 50
- Social
- 5
- Governance
- 69
- Women in the workforce
- 50%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Acarix AB's CADScor System uses phonocardiography for coronary artery disease monitoring.
- The CADScor System provides a two-minute heart sound recording with audio guidance for patients.
- Physicians, nurses, and technicians can use the CADScor System for rule-out diagnosis.
Weaknesses
- Acarix AB has only 9 employees, limiting operational capacity.
- The company's IPO occurred in 2016, indicating limited market presence.
- Acarix AB is headquartered in Malmö, Skåne, which may restrict regional reach.
Opportunities
- The Health Care sector offers growth potential for medical device monitoring solutions.
- Acarix AB can expand its CADScor System usage in the European market.
- The CADScor System's unique phonocardiography technique may attract new customers.
Threats
- The Health Care industry faces regulatory challenges for medical devices.
- Competition in the coronary artery disease monitoring market could increase.
- Acarix AB's small employee count may hinder rapid market response.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.